Capecitabine Tablet, Film Coated
Product Images NDC 62756-239

8 FDA label images from Sun Pharmaceutical Industries, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 62756-239). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Chemical Structure)

Chemical Structure (Chemical Structure)
Chemical structure of Capecitabine, showing its molecular components and arrangement including a fluorinated pyrimidine and sugar moiety with an attached ester group.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A survival curve comparing two treatment groups over months since randomization. The groups are 5-FU + Leucovorin and Capecitabine, with survival proportions on the y-axis and time in months on the x-axis. The graph also includes the number of patients at risk for each group at different time points.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A survival curve chart comparing two treatment groups: 5-FU + Leucovorin and Capecitabine. The x-axis represents months since randomization, and the y-axis shows survival probability. Below the graph, the number of patients at risk at various time points is listed for each treatment group.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A survival curve chart comparing estimated probability over time (in days) for two treatment groups: 5-FU + Leucovorin (Mayo Regimen) and Capecitabine 1250 mg/sqm twice daily intermittent. The chart shows probability decreasing over approximately 1500 days, with both groups following a similar survival trend.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A Kaplan-Meier survival curve comparing estimated probability over time (days) for two chemotherapy treatment groups: Docetaxel 100 mg/sqm every 3 weeks and Capecitabine 1250 mg/sqm twice daily intermittent with Docetaxel 75 mg/sqm every 3 weeks. The graph shows survival probabilities from 0 to around 700 days.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A Kaplan-Meier survival curve comparing estimated probability over time (days) for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks (solid line). The chart shows survival probability decreasing across approximately 800 days with median survival times indicated near 351.5 and 442 days.*
FDA Label Image

150mg-label (150mg Label)

150mg-label (150mg Label)
Label for Capecitabine Tablets, USP 150 mg, oral film-coated tablets. The label indicates 60 tablets per container. It includes the Sun Pharmaceutical Industries, Inc. logo and the NDC number 62756-238-86.*
FDA Label Image

500mg-label (500mg Label)

500mg-label (500mg Label)
Label for Capecitabine Tablets, USP 500 mg, film-coated oral tablets. The label indicates prescription use with a package count of 30 tablets. The product is labeled by Sun Pharmaceutical Industries, Inc., and displays a barcode and NDC 62756-239-83.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.